Bexion Pharmaceuticals, Inc. announced today that the Company will present at Biotech Showcase 2024 during the J.P. Morgan 42nd Annual Healthcare Conference week. Biotech Showcase 2024 will be held in-person, from January 8-10, 2024, in San Francisco, CA.
| Company now enrolling a Phase 1b/2 study in 1st Line mCRC and a PK/PD study in CIPN COVINGTON, Ky., Jan. 5, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company will present at Biotech Showcase 2024 during the J.P. Morgan 42nd Annual Healthcare Conference week. Biotech Showcase 2024 will be held in-person, from January 8-10, 2024, in San Francisco, CA.
Presentation Details: Scott Shively, CEO and President of Bexion Pharmaceuticals, and Joyce LaViscount, Chief Financial Officer of Bexion Pharmaceuticals, will attend the conference. Additionally, the Bexion management team will host one-on-one meetings with potential investors in San Francisco from January 8-11, 2024. If you would like to schedule a meeting, please reach out to the Company’s Investor Contact below. About Bexion Pharmaceuticals Investor Contact: Media Contact:
SOURCE Bexion Pharmaceuticals, Inc. |
View original content to download multimedia:
